NAME
León Ferder, MD
POSITION TITLE
Professor and Chairman, Physiology Department
EDUCATION/TRAINING
INSTITUTION AND LOCATION
DEGREE
YEAR(s)
FIELD OF STUDY
Bartolome Mitre School, Argentina
University of Buenos Aires, Argentina
University of Buenos Aires, Argentina
BS
M.D.
Ph.D.
1961
1967
1975
Science
Medicine
Clinical Pharmacology
Positions and Employment
1-0
1-0
1-0
1975-1984
1-0
1992-1996
1992-2001
1996-2001
1-0
1-0
2003-Present
2004-Present
Medical Residency, Internal Medicine, University of Buenos Aires
Medical Residency, Internal Medicine, Brookdale University Hospital, NY
Fellowship, Nephrology, Brookdale University Hospital, New York
Associate Professor, Pharmacology Dept., University of Buenos Aires
Professor, Pharmacology Dept., University of Buenos Aires
Dean, Maimonides Medical School, Argentina
Associate Professor, Nephrology, University of Buenos Aires
Professor, Pharmacology Dept., Hebrew University, Argentina
Rector, Hebrew University, Argentina
Chief Experimental Nephrology, Univ. of B.A. Cardiovascular Institute
Professor and Chairman, Physiology Dept., Ponce School of Medicine, PR
Professor and Chairman, Pharmacology Dept., Ponce School of Medicine, PR
1-0
1-0
1-0
1-0
1-0
1-0
2-0
2-0
1
1985
1-0
1-0
1993-1998
1995-1997
1996-1998
1-0
1-0
198-Present
1
2003-Present
Acting Chief, Nephrology, Teodoro Alvarez Hospital, Argentina
Treasurer of the Argentine Society of Pharmacology and Therapeutics.
Coordinator, Argentine Interdisciplinary Group of Hypertension, Argentine Society of Cardiology
Chief, Nephrology and Hypertension, Jewish Hospital of Buenos Aires
President of the Argentine Society of Pharmacology and Therapeutics
Member, High Blood Pressure Committee, National Public Health Department, Argentina
Member, National Committee for New Drug Control, National Public Health Department, Argentina
Founder Member, Argentine Council of Hypertension, Argentine Society of Cardiology
Founder Member, Interamerican Society of Pharmacology and Therapeutics
President, Argentine Council of Drugs and Kidney, Argentine Society of Nephrology
Treasurer, Argentine Society of Nephrology.
Director, Council of Hypertension. Argentine Society of Nephrology
Member, Academic Council, Hebrew University, Argentina
Director, Argentine Council of Drugs and Kidney, Buenos Aires Nephrological Society
Director, Institute for Biomedical Research, Hebrew University, Argentina
Medical Director, Albert Einstein Medical Research Center, Buenos Aires
President, Argentine Nephrological Association of Buenos Aires
Co-Editor, Latin American Journal of Nephrology, official publication of the Latin American Society of Nephrology and Hypertension
General Coordinator, “National Kidney Week”, Argentine Society of Nephrology
2003-Present Member, Association of Chairpersons of Departments of Physiology
Research Interest
Our research focuses in the Renin-Angiotensine-Aldosterone system but with aspects related to aging, proinflammatory and profibrotic mechanisms and the insulin-resistance. The hypothesis of our work leads in the mitochondrial function, where most of these mechanisms already mentioned take place. Blocking Angiotensin II may decrease the intramithochondiral oxidative stress, changing the biology of the cell, regulating apoptosis and other common mechanisms in cardiovascular diseases.
Research Support
Ontarget Study 2002-Present
Boehringer Ingelheim
Clinical Pharmacology Research: ONTARGET will assess the efficacy of the angiotensin II receptor blocker Telmisartan alone, and in combination with the angiotensin converting enzyme inhibitor ramipril, and will compare these to the efficacy of ramipril alone. Endpoints will include the reduction of risk of cardiovascular mortality, stroke, myocardial infarction and hospitalization for congestive heart failure. Role: Co-Investigator
Selected Peer-reviewed publications
Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissues. EMV de Cavanagh, F Inserra, L Ferder, CG Fraga. Am J Physiol, Regulatory Integrative Comp Physiol 278:R572-R577, 2000.
Morphologic changes in cavernous tissue in spontaneous hypertensive rats. JE Toblli, I Stella, F Inserra, L Ferder, F Zeller, ON Mazza. Am J Hypertens 13:686-692, 2000.
The irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. The Collaborative Study Group, Nephrol Dial Transplant 15:487-497, 2000.
Effects of dehydroepiandrosterone and quinapril on nephropathy in obese Zucker rats. Richards RJ, Porter JR, Inserra F, Ferder LF, Stella I, Reisin E, Svec F. Kidney Int 59(1): 37-43, 2001.
Protective role of enalapril for chronic tubulointerstitial lesions of hyperoxaluria. Toblli JE, Ferder L, Stella I, Angerosa M, Inserra F. J Urol 166(1):275-80, 2001.
Enalapril attenuates oxidative stress in diabetic rats. Cavanagh EM, Inserra F, Toblli J, Stella I, Fraga CG, Ferder L. Hypertension 38(5): 1130-6, 2001.
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. RENAAL Study Investigators, N Engl J Med 345(12):861-869, 2001.
Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. Toblli JE, Ferder L, Stella I, De Cavanaugh EM, Angerosa M, Inserra F. J Urol. 2002 Oct;168(4 Pt 1):1550-5
Enalapril prevents fatty liver in nephrotic rats. Toblli JE, Ferder L, Stella I, Angerosa M, Inserra F. J Nephrol. 2002 Jul-Aug; 15(4):358-67.
Advances in our understanding of aging: role of the renin-angiotensin system. Ferder L, Inserra F, Basso N. Curr Opin Pharmacol. 2002 Apr;2(2):189-94.
Effects of renin-angiotensin system blockade in the aging kidney. Ferder LF, Basso N. Exp Gerontol. 2003 Mar;38(3):237-44.
Enalapril and losartan attenuate mitochondrial dysfunction in aged rats . Elena M. V. de Cavanagh, Barbara Piotrkowski, Nidia Basso, Ines Stella, Felipe Inserra, Leon Ferder, and Cesar G. Fraga. FASEB J. published Apr 22, 2003, 10.1096
Basso, N., Stella, I., de Cavanagh, E.M., Ferder, L.F., Lores, A., Inserra, F., Protective effect of the inhibition of the renin-angiotensin system on ageing. Reg. Pep. 2004 in press.
Toblli JE, Stella I, Mazza ON, Ferder L, Inserra F., Candesartan cilexetil protects cavernous tissue in spontaneously hypertensive rats. Int J Impot Res. 2004 Apr 22.
Toblli J, Stella I, Nestor Mazza O, Ferder L, Inserra F., Protection of cavernous tissue in male spontaneously hypertensive rats: beyond blood pressure control. Am J Hypertens. 2004 Jun;17(6):516-22.
